bis(1-chloroethyl) sulfide | 40709-87-3

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醚类
• 英文名称: bis(1-chloroethyl) sulfide
• 英文别名: bis(1-chloroethyl)sulfane；Bis-(α-chlorethyl)-sulfid；1,1'-Dichlor-diethylthioether；Bis-(1-chlorethyl)-sulfid；α.α'-Dichlor-diaethylsulfid；Bis-(α-chlor-aethyl)-sulfid；1,1'-thiobis(1-chloro-ethane)；1.1'-Dichlor-diaethylsulfid；Bis-(1-chloraethyl)-sulfid；1-Chloro-1-[(1-chloroethyl)sulfanyl]ethane；1-chloro-1-(1-chloroethylsulfanyl)ethane
• CAS: 40709-87-3
• 化学式: C₄H₈Cl₂S
• 分子量: 159.08
• InChiKey: YLMWJABSFQMYNP-UHFFFAOYSA-N

物化性质

• 沸点：
  76-77 °C(Press: 41 Torr)
• 密度：
  1.1992 g/cm3(Temp: 14 °C)

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  7
• 可旋转键数：
  2
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  25.3
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  bis(1-chloroethyl) sulfide 在 2-氯乙醇 作用下， 生成 1,3,5-三噻烷
  参考文献：
  名称：

  Bales; Nickelson, Journal of the Chemical Society, 1923, vol. 123, p. 2489

  摘要：

  DOI：
• 作为产物：
  描述：

  三聚乙醛 在 盐酸 、 硫化氢 作用下， 生成 bis(1-chloroethyl) sulfide
  参考文献：
  名称：

  Brandsma,L.; Arens,J.F., Recueil des Travaux Chimiques des Pays-Bas, 1961, vol. 80, p. 237 - 240

  摘要：

  DOI：
• 作为试剂：
  描述：

  5-甲基-2-苯基-1,2-二氢吡唑-3-酮 、 sodium methylate 在 bis(1-chloroethyl) sulfide 作用下， 生成 (5-methyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazol-4-yl)-(3-methyl-5-oxo-1-phenyl-1,5-dihydro-pyrazol-4-ylidene)-methane 、 5,5'-dimethyl-2,2'-diphenyl-1,2,1',2'-tetrahydro-4,4'-methanediyl-bis-pyrazol-3-one
  参考文献：
  名称：

  Selective Neck Dissection for the Treatment of Neck Metastasis From Squamous Cell Carcinoma of the Head and Neck

  摘要：

  AbstractObjective Our objective was to determine the proportion of patients disease free in the neck, with the primary site controlled, who have been treated with a selective neck dissection (SND) for squamous cell carcinoma (SCCa) of the upper aerodigestive tract, and who had cervical metastasis less than 3 cm.Study Design A cohort of patients who fit the inclusion/exclusion criteria was identified retrospectively. Then all surviving patients were followed for a minimum of 2 years.Methods A group of 52 patients who had 58 selective neck dissections for cervical metastases from SCCa of the upper aerodigestive tract were identified. The mean age was 56 years (range, 20–85 y), there were 40 males and 12 females, and mean follow‐up was 24.5 months (range, 1–64 mo). Twenty‐six patients had clinically negative (cN0) neck examinations and 26 had clinically positive neck examinations. Postoperative radiation was given for extracapsular spread, greater than 2 positive nodes, T3, T4, or recurrent disease if the patient had not received radiation before surgery. These radiation criteria excluded 18 patients from postoperative radiation treatment.Results Kaplan‐Meier survival analysis showed that the regional control rate with the primary site controlled was 0.94. Six patients developed recurrent neck disease. Three of these 6 patients were surgically salvaged. Four recurrences were in the dissected field and 2 were out of the dissected field (level V).Conclusions With similar indications for radiation therapy, the regional control rate in this cohort is comparable to control rates obtained with modified radical neck dissection.

  DOI：

  10.1097/00005537-200203000-00005

文献信息

• [EN] NITROXYL (HNO) RELEASING COMPOUNDS AND USES THEREOF IN TREATING DISEASES<br/>[FR] COMPOSÉS LIBÉRANT DU NITROXYLE (HNO) ET LEURS UTILISATIONS DANS LE TRAITEMENT DE MALADIES
  申请人：US HEALTH

  公开号：WO2011116336A1

  公开（公告）日：2011-09-22

  Disclosed is a compound of the formula (I) or a pharmaceutically acceptable salt thereof:(I) in which R1, R2, R3, and R4 are defined herein and pharmaceutical compositions thereof. Further provided is a method of treating various disorders, such as a disorder selected from the group consisting of a cardiovascular disorder, cancer, chronic pain, alcohol dependence, and inflammation in a patient comprising administering an effective amount of a compound or pharmaceutically acceptable salt of formula (I).

  披露了一种公式(I)的化合物或其药物可接受的盐：(I)其中R1、R2、R3和R4按本说明书定义，以及其药物组合物。进一步提供了一种治疗各种疾病的方法，例如从心血管疾病、癌症、慢性疼痛、酒精依赖和炎症中选择的一种疾病，包括向患者施用公式(I)的化合物或药物可接受的盐的有效量。
• [EN] COMPOSITIONS AND METHODS OF DIAZENIUMDIOLATE-BASED PRODRUGS FOR TREATING CANCER<br/>[FR] COMPOSITIONS DE PROMÉDICAMENTS À BASE DE DIAZÉNIUMDIOLATE POUR LE TRAITEMENT DU CANCER ET PROCÉDÉS
  申请人：UNIV ARIZONA STATE

  公开号：WO2016073835A1

  公开（公告）日：2016-05-12

  The present disclosure provides methods utilizing the diazeniumdiolate-based prodrugs for the treatment of cancer via various mechanisms and procedures. The disclosure also provides kits comprising the diazeniumdiolate-based prodrugs. Despite the fact that there have been significant developments in anti-cancer technology, such as radiotherapy, chemotherapy and hormone therapy, cancer still remains the second leading cause of death following heart disease in the United States. Most often, cancer is treated with chemotherapy utilizing highly potent drugs.

  本公开提供了一种利用基于偶氮双酸盐的前药治疗癌症的方法，通过各种机制和程序。本公开还提供了包含基于偶氮双酸盐的前药的试剂盒。尽管在抗癌技术方面取得了重大进展，如放射治疗、化学治疗和激素治疗，但癌症在美国仍然是继心脏病之后的第二大死因。通常，癌症使用高活性药物进行化疗。
• [EN] ANTIVIRAL COMPOUNDS<br/>[FR] COMPOSÉS ANTIVIRAUX
  申请人：ALIOS BIOPHARMA INC

  公开号：WO2015026792A1

  公开（公告）日：2015-02-26

  Disclosed herein are new antiviral compounds, together with pharmaceutical compositions that include one or more antiviral compounds, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a paramyxovirus viral infection with one or more small molecule compounds. Examples of paramyxovirus infection include an infection caused by human respiratory syncytial virus (RSV).

  本文披露了新的抗病毒化合物，以及包括一种或多种抗病毒化合物的药物组合物，以及合成这些化合物的方法。本文还披露了使用一种或多种小分子化合物改善和/或治疗副粘病毒病毒感染的方法。副粘病毒感染的例子包括由人类呼吸道合胞病毒（RSV）引起的感染。
• ANTI-INFLAMMATORY COMPOUND, AND PREPARATION AND USE THEREOF
  申请人：VivaVision Biotech, Inc.

  公开号：US20200377460A1

  公开（公告）日：2020-12-03

  The present invention provides an anti-inflammatory compound, which is a compound having a structure (I) as shown below: The compound is a target that is important for autoimmune activation, and that has strong inhibitory effect on PDE4 and penetrates the skin easily, and is a new type anti-inflammatory compound that is easily degraded.

  本发明提供一种抗炎化合物，该化合物具有如下所示的结构（I）： 该化合物是一个重要的自身免疫激活靶点，对PDE4具有强烈的抑制作用，易于渗透皮肤，并且是一种易于降解的新型抗炎化合物。
• 18F-LABELED PRECURSOR OF PET RADIOACTIVE MEDICAL SUPPLIES, AND PREPARATION METHOD THEREOF
  申请人：Chi Dae-Yoon

  公开号：US20140194620A1

  公开（公告）日：2014-07-10

  The present invention relates to a precursor of positron emission tomography (PET) radioactive medical supplies, a preparation method thereof, and an application thereof, and more specifically, to a precursor having a tetravalent organic salt leaving group, a preparation method, and a method for preparing desired PET radioactive medical supplies in a high radiochemical yield within a short preparation time by introducing 18 F using the same through a single step. The precursor having a tetravalent organic salt leaving group of the present invention can simplify the known complex multistep preparation of radioactive medical supplies into a single step, can save production costs because an excessive amount of a phase transfer catalyst is not required, facilitates separation of a compound after reaction, and enables rapid reaction velocity. The features are appropriate for the mass production of PET radioactive medical supplies by an automated synthesis system.

  本发明涉及正电子发射断层扫描（PET）放射性医疗用品的前体、其制备方法及应用，更具体地，涉及一种具有四价有机盐离基的前体、其制备方法，以及通过引入 18 F并通过单步骤使用相同物质在短时间内高放射化学产率制备所需PET放射性医疗用品的方法。本发明的具有四价有机盐离基的前体可以将已知的复杂多步制备放射性医疗用品简化为单步骤，因为不需要过量的相转移催化剂，可以节省生产成本，促进反应后化合物的分离，并实现快速反应速度。这些特点适用于通过自动合成系统大规模生产PET放射性医疗用品。